Latest Market News

May 25
Market Spotlight: FOMC Minutes on Deck Tonight

USD Poised for FOMC MovesTonight’s FOMC minutes release will of course be centre stage for traders. The recent squaring of long positions in USD puts the Dollar in a very interesting place ahead of the event because on the one hand, if the minutes are encouraging for USD, there is plenty of room for capital […]

May 25
Market Spotlight: GBPCAD Upside Potential

GBPCAD On Watch Price action in GBPCAD is looking interesting here. The pair has been moving lower in a tight bearish channel over recent months. However, the most recent lows saw strong bullish divergence with price subsequently breaking out above the bear channel highs. In light of these movements, we are now potentially dealing with […]

May 25
Coronavirus tally: New form of omicron subvariant BA.2 has become dominant among new COVID cases in the U.S.

As predicted by health care experts, a new form of the omicron subvariant BA.2 has become dominant among new cases of COVID-19 in the U.S., the New York Times reported, citing data from the Centers for Disease Control and Prevention, which estimates it accounted for about 58% of all new cases in the week through […]

May 25
Press release on the suspension of trading in Beluga

ANNOUNCEMENT BY THE FINANCIAL SERVICES AND MARKETS AUTHORITY, PUBLISHED IN APPLICATION OF ARTICLE 78 OF THE LAW OF 21 NOVEMBER 2017 Trading in the financial instruments of Beluga, ISIN BE0003723377, on Euronext Brussels is suspended from 25/05/2022 at 11:30 CET until the publication of a press release. Source: FSMA

May 25
WEF 2022: Trust and clarity are missing in discussions of carbon emissions and crypto

Panelists at the World Economic Forum session on crypto’s carbon footprint seem to be seeing FUD galore surrounding the environmental consequences of crypto mining. 847 Total views 50 Total shares The need for a clear, balanced concept of the issue was a constant theme at the panel discussion of crypto’s carbon footprint at the 2022 […]

May 25
INmune Bio stock plunges after clinical hold of IND of Alzheimer’s treatment prompts analyst downgrade

Shares of INmune Bio Inc. INMB, -24.62% plummeted 31.4% toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New Drug (IND) application to initiate its Phase 2 trial of its XPro Alzheimer’s treatment on […]